We hypothesize that GSH depletion after naringenin treatment, as reported by other authors, is mediated by multidrug resistance protein 1 (MRP1), which promotes increased sensitivity of cancer cells [6,30,37,38]. The gene discussed is ABCB1; the disease is cancer.